Display options
Cite
Versiani M, Nardi AE, Figueira I. Pharmacotherapy of dysthymia: review and new findings. Eur Psychiatry. 1998;13(4):203-9doi: 10.1016/S0924-9338(98)80005-9.
Versiani, M., Nardi, A. E., & Figueira, I. (1998). Pharmacotherapy of dysthymia: review and new findings. European psychiatry : the journal of the Association of European Psychiatrists, 13(4), 203-9. https://doi.org/10.1016/S0924-9338(98)80005-9
Versiani, M, et al. "Pharmacotherapy of dysthymia: review and new findings." European psychiatry : the journal of the Association of European Psychiatrists vol. 13,4 (1998): 203-9. doi: https://doi.org/10.1016/S0924-9338(98)80005-9
Versiani M, Nardi AE, Figueira I. Pharmacotherapy of dysthymia: review and new findings. Eur Psychiatry. 1998 Jul;13(4):203-9. doi: 10.1016/S0924-9338(98)80005-9. PMID: 19698626.
Copy Download .nbib Format: NLM
Share it on

Eur Psychiatry. 1998 Jul;13(4):203-9. doi: 10.1016/S0924-9338(98)80005-9.

Pharmacotherapy of dysthymia: review and new findings.

European psychiatry : the journal of the Association of European Psychiatrists

M Versiani, A E Nardi, I Figueira

Affiliations

  1. Institutional Affiliation, Institute of Psychiatry, Federal University of Rio de Janeiro, Anxiety and Depression Research Program, Rio de Janeiro, Brazil.

PMID: 19698626 DOI: 10.1016/S0924-9338(98)80005-9

Abstract

Open trials with tricyclics, classical monoamine oxidase inhibitors (MAOIs) or lithium in dysthymia yielded a response rate in 45% of subjects. A long-term treatment of dysthymia with 276 patients treated during 4 years with either moclobemide, tranylcypromine or a combination of amitryptiline plus chlordiazepoxide is described. After discontinuation there was a relapse rate of 89.1%. The controlled studies with tricyclics, MAOIs, reversible inhibitors of monoamine oxidase (RIMAs), specific serotonin reuptake inhibitor (SSRIs) or benzamides showed that drugs well-tolerated work better in dysthymia, due to the fact that the treatment must be long-term. Sertraline was studied vs placebo or imipramine in primary dysthymia. Moclobemide, imipramine and placebo were also studied in 315 patients. Mean doses were 650 mg/d of moclobemide and 203.2 mg/d of imipramine. Moclobemide and sertraline were both efficacious and well tolerated. In a long term treatment the clinician should assess the risk-benefit ratio. Dysthymic patients are very sensitive to unwanted effects and compliance is a serious issue.

Publication Types